'Super-antibodies' could curb COVID-19 and help avert future pandemics
Elie Dolgin • Jun 22, 2021
Companies are designing next-generation antibodies modeled on those taken from unique individuals whose immune systems can neutralize any COVID-19 variant — and related coronaviruses, too.
The US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in late May to sotrovimab, providing a new therapeutic weapon in the fight against SARS-CoV-2—and future coronaviruses with pandemic potential.
According to analysts and researchers alike, so-called super-antibodies such as sotrovimab should have an edge over first-generation monoclonal antibody (mAb) therapies for COVID-19 because of their broad neutralization capacity in the face of emerging virus variants.
Continue reading at Nature Biotechnology.
Drug trial results show that vaccines aren't the only use for the mRNA technology behind the most widely used COVID-19 jabs.
FDA panel’s green light on glaucoma wearable device offers hope in sight.